Patent US4435385A successfully refreshed from Google Patents.
US4435385A
Expired / Lapsed
US
⏱️ 0.0 years remaining
N-Acyl-polypeptides and processes for the production thereof
Assignee: FIRST NATIONAL STATE BANK NEWARK NEW JERSEY
•
Filing: 1982-03-02
•
Granted: 1984-03-06
•
Expires: 2002-03-02
Abstract
Abstract N-Acyl-polypeptides comprising the basic sequence <IMAGE> wherein "Acyl" is the acyl residue of an organic or inorganic acid; A is H or alkyl; >N-CH(Z)-CO- and E are the residues of natural alpha -amino acids or corresponding (D)-amino acids; C is -Trp- or -(D)Trp-; F is a terminal grouping; and Y1 and Y2 are each H or together are a direct bond; as well as their salt forms and complexes.
Inventors
- 👤 Wilfried Bauer
- 👤 Janos Pless
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 05:00
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/26
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
392 words
An N-acyl-polypeptide of formula I, ##STR18## where "Acyl" is (a) R I CO-- wherein R I is C 1-20 alkyl, C 3-20 alkenyl, C 3-20 alkinyl, phenyl, naphthyl or C 7-10 (phenylalkyl); (b) R II SO 2 -- wherein R II is C 1-10 alkyl, phenyl or C 7-10 (phenylalkyl); (c) R III O--CO-- wherein R III is C 1-10 alkyl or C 7-10 (phenylalkyl); and ##STR19## wherein R IV is hydrogen, C 1-10 alkyl, phenyl or C 7-10 (phenylalkyl) and R V is hydrogen or C 1-10 alkyl, A is hydrogen or C 1-3 alkyl, >N--CH(Z)--CO-- is (a) an (L)- or (D)-phenylalanine residue optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, or (b) the residue of a natural α-amino acid in which Z is alkyl of 3 to 4 carbon atoms, B is --Phe-- optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, C is --Trp-- or (D)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, D is --Lys-- optionally α-N-methylated and optionally ε-N-C 1-3 alkylated, E is --Thr-- or --(D)--Thr-- optionally α-N-methylated, F is a group of formula --COOR 1 , --CH 2 OR 2 , ##STR20## or ##STR21## wherein R 1 is hydrogen or C 1-3 alkyl, R 2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester, R 3 is hydrogen or methyl, R 4 is --CH(R 5 )--X, R 5 is hydrogen, --(CH 2 ) 2 --OH, --(CH 2 ) 3 --OH, --CH 2 --OH, --CH(CH 3 )--OH or isobutyl, and X is a group of formula --COOR 1 , --CH 2 OR 2 or ##STR22## wherein R 1 and R 2 are as defined above, R 6 is hydrogen or C 1-3 alkyl and R 7 is hydrogen, C 1-3 alkyl, phenyl or C 7-10 phenylalkyl, the group --CH(R 5 )--X having the (D)- or (L)-configuration, and Y 1 and Y 2 are each hydrogen or together represent a direct bond, whereby the residues in the 2- and 7-position each independently have the (L)- or (D)-configuration, and with the proviso that (L)- and/or (D)-cysteine residues are present at the 2- and 7-positions only, or a pharmaceutically acceptable salt or complex thereof.
Claim 2
Dependent Claim
392 words
An N-acyl-polypeptide of formula I, ##STR18## where "Acyl" is (a) R I CO-- wherein R I is C 1-20 alkyl, C 3-20 alkenyl, C 3-20 alkinyl, phenyl, naphthyl or C 7-10 (phenylalkyl); (b) R II SO 2 -- wherein R II is C 1-10 alkyl, phenyl or C 7-10 (phenylalkyl); (c) R III O--CO-- wherein R III is C 1-10 alkyl or C 7-10 (phenylalkyl); and ##STR19## wherein R IV is hydrogen, C 1-10 alkyl, phenyl or C 7-10 (phenylalkyl) and R V is hydrogen or C 1-10 alkyl, A is hydrogen or C 1-3 alkyl, >N--CH(Z)--CO-- is (a) an (L)- or (D)-phenylalanine residue optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, or (b) the residue of a natural α-amino acid in which Z is alkyl of 3 to 4 carbon atoms, B is --Phe-- optionally ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, C is --Trp-- or (D)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, NO 2 , NH 2 , OH, C 1-3 alkyl and/or C 1-3 alkoxy, D is --Lys-- optionally α-N-methylated and optionally ε-N-C 1-3 alkylated, E is --Thr-- or --(D)--Thr-- optionally α-N-methylated, F is a group of formula --COOR 1 , --CH 2 OR 2 , ##STR20## or ##STR21## wherein R 1 is hydrogen or C 1-3 alkyl, R 2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester, R 3 is hydrogen or methyl, R 4 is --CH(R 5 )--X, R 5 is hydrogen, --(CH 2 ) 2 --OH, --(CH 2 ) 3 --OH, --CH 2 --OH, --CH(CH 3 )--OH or isobutyl, and X is a group of formula --COOR 1 , --CH 2 OR 2 or ##STR22## wherein R 1 and R 2 are as defined above, R 6 is hydrogen or C 1-3 alkyl and R 7 is hydrogen, C 1-3 alkyl, phenyl or C 7-10 phenylalkyl, the group --CH(R 5 )--X having the (D)- or (L)-configuration, and Y 1 and Y 2 are each hydrogen or together represent a direct bond, whereby the residues in the 2- and 7-position each independently have the (L)- or (D)-configuration, and with the proviso that (L)- and/or (D)-cysteine residues are present at the 2- and 7-positions only, or a pharmaceutically acceptable salt or complex thereof.
Claim 3
Dependent Claim
59 words
An N-acyl-polypeptide according to claim 1, wherein "Acyl" is a group R I CO-- or R II SO 2 --, wherein R I is C 1-20 alkyl, C 3-20 alkenyl, C 3-20 alkinyl, phenyl, naphthyl or C 7-10 phenylalkyl; and R II is C 1-10 alkyl, phenyl or C 7-10 (phenylalkyl), or a pharmaceutically acceptable salt or complex thereof.
Claim 4
Dependent Claim
28 words
An N-acyl-polypeptide according to claim 2, wherein R I is C 7-15 alkyl and R II is C 7-10 alkyl, or a pharmaceutically acceptable salt or complex thereof.
Claim 5
Dependent Claim
22 words
An N-acyl-polypeptide according to claim 2, wherein "Acyl" is a group R I CO--, or a pharmaceutically acceptable salt or complex thereof.
Claim 6
Dependent Claim
19 words
An N-acyl-polypeptide according to claim 1 of formula CH.sub.3 (CH.sub.2).sub.8 -CO-(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys-Thr-ol or a pharmaceutically acceptable salt or complex thereof.
Claim 7
Dependent Claim
115 words
A polypeptide according to claim 1 of the formula ##STR23## where "Acyl" is R I CO or R II SO 2 ; R I is C 1-15 alkyl, phenyl or C 7-10 (phenylalkyl); R II is C 1-10 alkyl or phenyl optionally substituted by C 1-3 alkyl; A is hydrogen; >N--CH(Z)--CO-- is --(D)--Phe or --(D)--Nle--; B is --Phe--; C is --(D)--Trp--; D is --Lys--; E is --Thr--; F is ##STR24## R 3 is hydrogen; R 5 is --CH 2 OH; --CH(CH 3 )OH or isobutyl; X is --CH 2 OR 2 ; R 2 is hydrogen and Y 1 and Y 2 together represent a direct bond; or a pharmaceutically acceptable salt or complex thereof.
Claim 8
Dependent Claim
20 words
A compound according to claim 1 in which "Acyl" is R I CO-- wherein R I is C 1-15 alkyl.
Claim 9
Dependent Claim
11 words
A compound according to claim 1 in which >N--CH(Z)--CO-- is --(D)--Phe--.
Claim 10
Dependent Claim
18 words
A compound according to claim 1 in which R 5 is --CH 2 OH or --CH(CH 3 )OH.
Claim 11
Dependent Claim
15 words
The compound according to claim 1 which is ##STR25## pharmaceutically acceptable salt or complex thereof.
Claim 12
Dependent Claim
72 words
A compound according to claim 1 of the formula ##STR26## in which Acyl is selected from the group consisting of CH 3 CO, CH 3 (CH 2 ) 4 CO--, CH 3 (CH 2 ) 6 CO--, CH 3 (CH 2 ) 7 CO--, CH 3 (CH 2 ) 10 CO--, CH 3 (CH 2 ) 12 CO-- and t.C 4 H 9 --CO-- or a pharmaceutically acceptable salt or complex thereof.
Claim 13
Dependent Claim
45 words
A compound according to claim 1 of the formula ##STR27## in which Acyl is selected from the group consisting of ##STR28## C 2 H 5 NH--CO--, D(+)-Biotinyl and CH 3 (CH 2 ) 9 SO 2 -- or a pharmaceutically acceptable salt or complex thereof.
Claim 14
Dependent Claim
13 words
The pharmaceutical composition according to claim 10 in which the N-Acyl-polypeptide is ##STR29##
Claim 15
Dependent Claim
12 words
The method according to claim 11 in which the N-Acyl-polypeptide is ##STR30##
Claim 16
Dependent Claim
12 words
The method according to claim 13 in which the N-Acyl-polypeptide is ##STR31##
Claim 17
Dependent Claim
42 words
A pharmaceutical composition useful in inhibiting GH secretion and in treating gastrointestinal disorders comprising an effective amount of an N-acyl-polypeptide as defined in claim 1 or a pharmaceutically acceptable salt or complex thereof, together with a pharmaceutically acceptable diluent or carrier therefor.
Claim 18
Dependent Claim
50 words
A method of treating disorders with an aetiology comprising or associated with excess GH-secretion, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of an N-acyl-polypeptide as defined in claim 1 or of a pharmaceutically acceptable salt form or complex thereof.
Claim 19
Dependent Claim
15 words
A method according to claim 17 for the treatment of diabetes mellitus, angiopathy or acromegaly.
Claim 20
Dependent Claim
42 words
A method of treating gastro-intestinal disorders in a subject in need of such treatment, which method comprises administering to said subject an effective amount of an N-acyl-polypeptide as defined in claim 1 or of a pharmaceutically acceptable salt form or complex thereof.
Claim 21
Dependent Claim
17 words
A method according to claim 19 for the treatment of gastric ulcer, gastro-intestinal bleeding or acute pancreatitis.
References Cited (Backward Citations)
US3904594A
Cited
US4282143A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-06 | 1987-09-05 | 1988-03-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-06 | 1991-09-05 | 1992-03-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-06 | 1995-09-05 | 1996-03-06 | $7700.00 | Window Closed / Lapsed |